Showing 10 posts of 10 posts found.

Pfizer image

Pfizer Gaucher drug rejected by CHMP

June 25, 2012
Sales and Marketing Elelyso, FDA, Gaucher, Pfizer, Shire, Vpriv

A European committee has refused marketing authorisation for Pfizer’s Gaucher disease drug Elelyso, as a competitor drug has exclusivity to …

Pfizer enters Gaucher disease market

May 3, 2012
Sales and Marketing Cerezyme, Elelyso, Gaucher, Genzyme, Pfizer, Shire, Vpriv

Pfizer has gained FDA approval for its new Gaucher disease drug Elelyso.  Elelyso (taliglucerase alfa) is an enzyme replacement therapy …

Shire's Vpriv website

Shire’s Vpriv website in breach of ABPI Code

April 24, 2012
Medical Communications, Sales and Marketing ABPI, Genzyme, PMCPA, Shire, Vpriv, code

Shire’s website for its Gaucher’s disease drug Vpriv has fallen foul of the ABPI’s Code of Conduct.  The complaint was …

Shire image

Shire’s Vpriv plant wins EU approval

February 28, 2012
Manufacturing and Production EMA, Shire, Vpriv

Shire has been told by the European Medicines Agency that it can make use of a manufacturing facility in Lexington, …

Shire picture

Robust sales for Shire

February 13, 2012
Sales and Marketing Replagal, Shire, Vpriv, Vyvanse

A rise in the use of attention deficit and hyperactivity disorder drugs has helped push Shire’s turnover past $4 billion …

Shire facility could answer rare disease drug shortage

November 27, 2011
Manufacturing and Production Fabry disease, Gaucher, Shire, Vpriv

Shire has filed applications with the European and US regulators to produce its Gaucher disease drug Vpriv (velaglucerase alfa) at …

Shire gets green light for second Replagal facility

June 28, 2011
Manufacturing and Production Replagal, Shire, Vpriv, pharma manufacturing news

The European Medicines Agency has approved a second manufacturing facility in the USA for Shire’s Fabry disease treatment Replagal. Shire’s …

Shire says new plant will add to Replagal, Vpriv capacity

January 17, 2011
Manufacturing and Production Cerezyme, Replagal, Shire, Vpriv

UK drugmaker Shire has completed construction of a new manufacturing facility for its orphan disease drugs Replagal and Vpriv, and …

Pfizer headquarters

Pfizer submits Gaucher drug to EMA

November 29, 2010
Sales and Marketing Cerezyme, EMA, Gaucher disease, Genzyme, Pfizer, Protalix BioTherapeutics, Shire, Vpriv, taliglucerase alfa

Pfizer and partner Protalix BioTherapeutics have submitted a marketing application to European regulator the EMA for their Gaucher disease candidate …

Shire readies Gaucher drug Vpriv

February 23, 2010
Manufacturing and Production Cerezyme, Gaucher's, Shire, Vpriv

Shire Pharmaceuticals says it has already manufactured enough of its Vpriv to treat around 400 Gaucher disease patients and could …

Latest content